US Stocks Closed Mixed as Tech Giants Gear Up for Earnings
In a day marked by a divergent performance across major indices, the stock market closed with a mixed bag as investors braced themselves for the
Home
Page 110
Longeveron Stock Dips Despite Landmark US Patent Approval
Longeveron Inc, a clinical-stage biotechnology company on the forefront of developing cellular therapies for life-threatening and chronic aging-related conditions, has announcement a patent allowance from
SoFi Technologies’ Q4 Earnings Reveals First Profit Since IPO
In a rollercoaster ride of trading patterns, SoFi Technologies saw a momentous surge of 22% in its stock value, reminiscent of July’s highs. The catalyst
GRI Bio Initiates 1-for-7 Reverse Stock Split, Stock Soars
In a bold move to reshape its market presence, GRI Bio Inc, a biotech trailblazer focused on NKT cell modulators for treating various diseases, recently
Palisade Bio Inc’s Warrants Exercise and Market Response
In a strategic move aimed at fortifying its financial position, Palisade Bio Inc, a biopharmaceutical company at the forefront of developing cutting-edge therapeutics for chronic
Sidus Space Initiates Public Offering, Stock Sinks
Sidus Space, a prominent player in the Space and Data-as-a-Service arena, has unveiled its underwritten public offering plans. The company, known for its innovative contributions
Q4 Unveiled: Big Tech Earnings Season Sets the Market Tempo
In the tumultuous landscape of Wall Street, the US stocks experienced a moderate dip on Tuesday, casting a shadow over the recent record highs. The
Cautious Ascent in US Stocks Amidst Economic Crosscurrents
In the cutthroat arena of Wall Street, Monday witnessed a cautious ascent in US stocks, with the S&P 500 etching yet another record close. As
Update Alert: Phunware Inc Shares Insights on Directorial Transitions
In a recent update, Phunware Inc has undergone notable changes in its board composition, leading to shifts in its leadership dynamics. Ryan Costello’s resignation from
Palisade Bio Surges Over 100 % on Positive Preclinical Data
Palisade Bio Inc, a dedicated biopharmaceutical company committed to pioneering therapeutics for serious chronic gastrointestinal (GI) diseases, has witnessed a remarkable upswing in its stock
